Ob/Gyn Medical News about Pharmacogenomics

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Benefits of Pharmacogenomics in Drug Development-Earlier Launch of Drugs and Less Adverse Events
The Journal of Medical Systems, 04/16/09

Ohashi W et al. - PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole. Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost–benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet.

<< Previous
Impact of Polycystic Ovary Syndrome on Selected Indicators of In...

Next >>
Adherence, compliance key with underinsured